These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38457359)

  • 1. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
    Hayashi RJ; Hermiston ML; Wood BL; Teachey DT; Devidas M; Chen Z; Annett RD; Asselin BL; August K; Cho S; Dunsmore KP; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju A; Lam A; Messinger YH; Miles RR; Okada M; Patel S; Schafer ES; Schechter T; Shimano KA; Singh N; Steele A; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay PA; Loh ML; Hunger SP; Raetz EA; Bollard CM; Allen CE
    Blood; 2024 May; 143(20):2053-2058. PubMed ID: 38457359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
    J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
    Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
    Burns MA; Place AE; Stevenson KE; Gutiérrez A; Forrest S; Pikman Y; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Gennarini LM; Kahn JM; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28719. PubMed ID: 33026184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.
    Orgel E; Tucci J; Alhushki W; Malvar J; Sposto R; Fu CH; Freyer DR; Abdel-Azim H; Mittelman SD
    Blood; 2014 Dec; 124(26):3932-8. PubMed ID: 25349177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    Hayashi RJ; Winter SS; Dunsmore KP; Devidas M; Chen Z; Wood BL; Hermiston ML; Teachey DT; Perkins SL; Miles RR; Raetz EA; Loh ML; Winick NJ; Carroll WL; Hunger SP; Lim MS; Gross TG; Bollard CM
    J Clin Oncol; 2020 Sep; 38(26):3062-3070. PubMed ID: 32552472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report.
    Gossai NP; Devidas M; Chen Z; Wood BL; Zweidler-McKay PA; Rabin KR; Loh ML; Raetz EA; Winick NJ; Burke MJ; Carroll AJ; Esiashvili N; Heerema NA; Carroll WL; Hunger SP; Dunsmore KP; Winter SS; Teachey DT
    Blood; 2023 Apr; 141(15):1802-1811. PubMed ID: 36603187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
    Horton TM; Whitlock JA; Lu X; O'Brien MM; Borowitz MJ; Devidas M; Raetz EA; Brown PA; Carroll WL; Hunger SP
    Br J Haematol; 2019 Jul; 186(2):274-285. PubMed ID: 30957229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
    Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
    Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
    Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
    Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prognostic factors in children with acute T-lymphoblastic leukemia: a single-center clinical study of the CCCG-ALL-2015 protocol].
    Fu WF; Fang YJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Oct; 26(10):1078-1085. PubMed ID: 39467678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
    Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].
    Wu CP; Zheng YZ; Li J; Wen H; Weng KZ; Zhuang SQ; Wu XG; Hua XL; Zheng H; Chen ZS; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):6-13. PubMed ID: 38387892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
    Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
    BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
    Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
    Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.